AstraZeneca arthritis pill performs poorly in new study

[riky]

AstraZeneca arthritis pill performs poorly in new study

<p><a href="http://news.yahoo.com/astrazeneca-arthritis-drug-mixed-results-phase-iii-trial-062120438--finance.html"><img src="http://l.yimg.com/bt/api/res/1.2/G1PcVyBX73nXyMPNzO_z0Q--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-04-05T062120Z_1_CBRE9340HNV00_RTROPTP_2_ASTRAZENECA-STRATEGY.JPG" width="130" height="86" alt="CEO of AstraZeneca, Pascal Soriot, poses for a photograph in this undated picture provided by AstraZeneca in London" align="left" title="CEO of AstraZeneca, Pascal Soriot, poses for a photograph in this undated picture provided by AstraZeneca in London" border="0" /></a>By Ben Hirschler LONDON (Reuters) - AstraZeneca's experimental rheumatoid arthritis pill fostamatinib met only one of two goals in a late-stage clinical trial, leaving the future of one of the group's few advanced pipeline products uncertain. Fostamatinib is a potential competitor to injectable drugs like AbbVie's Humira and a new pill from Pfizer called Xeljanz in a $20 billion-plus market. Disappointing results from earlier tests, however, mean investor hopes for the medicine are low. ...</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login